{
  "protocolSection": {
    "identificationModule": {
      "nctId": "NCT04358224",
      "orgStudyIdInfo": {
        "id": "R668-AD-1830"
      },
      "organization": {
        "fullName": "Bernstein Clinical Research Center",
        "class": "OTHER"
      },
      "briefTitle": "The Utility of Functionally Relevant Signature Genes in Assessing the Clinical Outcomes of Dupilumab Treatment",
      "officialTitle": "The Utility of Functionally Relevant Signature Genes in Assessing the Clinical Outcomes of Dupilumab Treatment"
    },
    "statusModule": {
      "statusVerifiedDate": "2023-02",
      "overallStatus": "COMPLETED",
      "expandedAccessInfo": {
        "hasExpandedAccess": false
      },
      "startDateStruct": {
        "date": "2020-09-01",
        "type": "ACTUAL"
      },
      "primaryCompletionDateStruct": {
        "date": "2022-11-18",
        "type": "ACTUAL"
      },
      "completionDateStruct": {
        "date": "2022-11-18",
        "type": "ACTUAL"
      },
      "studyFirstSubmitDate": "2020-04-14",
      "studyFirstSubmitQcDate": "2020-04-20",
      "studyFirstPostDateStruct": {
        "date": "2020-04-24",
        "type": "ACTUAL"
      },
      "lastUpdateSubmitDate": "2023-02-06",
      "lastUpdatePostDateStruct": {
        "date": "2023-02-08",
        "type": "ACTUAL"
      }
    },
    "sponsorCollaboratorsModule": {
      "responsibleParty": {
        "type": "SPONSOR_INVESTIGATOR",
        "investigatorFullName": "Jonathan A. Bernstein, MD",
        "investigatorTitle": "principal investigator",
        "investigatorAffiliation": "Bernstein Clinical Research Center"
      },
      "leadSponsor": {
        "name": "Jonathan A. Bernstein, MD",
        "class": "OTHER"
      }
    },
    "oversightModule": {
      "oversightHasDmc": false,
      "isFdaRegulatedDrug": true,
      "isFdaRegulatedDevice": false,
      "isUsExport": false
    },
    "descriptionModule": {
      "briefSummary": "The utility of functionally relevant signature genes in assessing the clinical outcomes of dupilumab treatment in the adult onset atopic dermatitis",
      "detailedDescription": "The study consists of 9 visits. Duplimab will used in the treatment of adult onset atopic dermatitis. Qualified subjects will receive 5 dupilumab open-label injections. Skin biopsies/ skin strips will be obtained at the beginning and the end of treatment. TARC and IgE levels will be obtained at the beginning and end of treatment. Subjects will complete daily diaries assessing atopic dermatitis symptoms. Patient reported out comes will be completed at each visit"
    },
    "conditionsModule": {
      "conditions": [
        "Atopic Dermatitis",
        "Eczema"
      ]
    },
    "designModule": {
      "studyType": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "designInfo": {
        "allocation": "NA",
        "interventionModel": "SINGLE_GROUP",
        "primaryPurpose": "TREATMENT",
        "maskingInfo": {
          "masking": "NONE"
        }
      },
      "enrollmentInfo": {
        "count": 12,
        "type": "ACTUAL"
      }
    },
    "armsInterventionsModule": {
      "armGroups": [
        {
          "label": "open-label",
          "type": "OTHER",
          "description": "open-label",
          "interventionNames": [
            "Biological: Dupilumab Prefilled Syringe"
          ]
        }
      ],
      "interventions": [
        {
          "type": "BIOLOGICAL",
          "name": "Dupilumab Prefilled Syringe",
          "description": "open-label",
          "armGroupLabels": [
            "open-label"
          ],
          "otherNames": [
            "dupixent"
          ]
        }
      ]
    },
    "outcomesModule": {
      "primaryOutcomes": [
        {
          "measure": "The primary objective of this study is to correlate cutaneous transcriptomes with before and after Dupilumab treatment outcomes in patients who meet the clinical diagnostic criteria for adult onset AD.",
          "description": "Data will be analyzed from skin punch biopsies from active skin lesions and uninvolved skin samples before and after treatment",
          "timeFrame": "after 6 months"
        }
      ],
      "secondaryOutcomes": [
        {
          "measure": "To investigate possible influence of Dupilumab on serologic protein biomarkers in patients with adult onset AD",
          "description": "Total IgE, TARC and eotaxin will be compared pre and post treatment",
          "timeFrame": "after 6 months"
        }
      ]
    },
    "eligibilityModule": {
      "eligibilityCriteria": "Inclusion Criteria:\n\n* history of adult onset atopic dermatitis\n\nExclusion Criteria:\n\n\\-",
      "healthyVolunteers": false,
      "sex": "ALL",
      "minimumAge": "19 Years",
      "maximumAge": "75 Years",
      "stdAges": [
        "ADULT",
        "OLDER_ADULT"
      ]
    },
    "contactsLocationsModule": {
      "overallOfficials": [
        {
          "name": "Jonathan Bernstein",
          "affiliation": "Bernstein Clinial Research Center",
          "role": "PRINCIPAL_INVESTIGATOR"
        }
      ],
      "locations": [
        {
          "facility": "Bernstein Clinical Research Center",
          "city": "Cincinnati",
          "state": "Ohio",
          "zip": "45231",
          "country": "United States",
          "geoPoint": {
            "lat": 39.12711,
            "lon": -84.51439
          }
        }
      ]
    },
    "ipdSharingStatementModule": {
      "ipdSharing": "YES",
      "description": "to be determined",
      "infoTypes": [
        "STUDY_PROTOCOL",
        "SAP",
        "CSR"
      ],
      "timeFrame": "at end of trial",
      "accessCriteria": "to be determined"
    }
  },
  "derivedSection": {
    "miscInfoModule": {
      "versionHolder": "2026-02-04"
    },
    "conditionBrowseModule": {
      "meshes": [
        {
          "id": "D003876",
          "term": "Dermatitis, Atopic"
        },
        {
          "id": "D004485",
          "term": "Eczema"
        }
      ],
      "ancestors": [
        {
          "id": "D012873",
          "term": "Skin Diseases, Genetic"
        },
        {
          "id": "D030342",
          "term": "Genetic Diseases, Inborn"
        },
        {
          "id": "D009358",
          "term": "Congenital, Hereditary, and Neonatal Diseases and Abnormalities"
        },
        {
          "id": "D003872",
          "term": "Dermatitis"
        },
        {
          "id": "D012871",
          "term": "Skin Diseases"
        },
        {
          "id": "D017437",
          "term": "Skin and Connective Tissue Diseases"
        },
        {
          "id": "D017443",
          "term": "Skin Diseases, Eczematous"
        },
        {
          "id": "D006969",
          "term": "Hypersensitivity, Immediate"
        },
        {
          "id": "D006967",
          "term": "Hypersensitivity"
        },
        {
          "id": "D007154",
          "term": "Immune System Diseases"
        }
      ]
    },
    "interventionBrowseModule": {
      "meshes": [
        {
          "id": "C582203",
          "term": "dupilumab"
        }
      ]
    }
  },
  "hasResults": false
}